Accessibility Menu
Vivos Therapeutics Stock Quote

Vivos Therapeutics (NASDAQ: VVOS)

$3.01
(1.3%)
+0.04
Price as of October 24, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$3.01
Daily Change
(1.3%) +$0.04
Day's Range
$2.95 - $3.11
Previous Close
$3.01
Open
$2.98
Beta
0
Volume
90,384
Average Volume
287,180
Market Cap
22.6M
Market Cap / Employee
$3.01M
52wk Range
$1.98 - $7.95
Revenue
-
Gross Margin
0.51%
Dividend Yield
N/A
EPS
-$1.88
CAPs Rating
-
Industry
Healthcare Providers and Services

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Vivos Therapeutics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
VVOS+12.73%N/AN/A-99%
S&P+16.9%+95.99%+14.39%+85%

Vivos Therapeutics Company Info

Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman on July 7, 2016 and is headquartered in Littleton, CO.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$3.82M-5.8%
Gross Profit$1.80M-28.0%
Gross Margin47.23%-14.6%
Market Cap$18.61M146.8%
Market Cap / Employee$0.17M0.0%
Employees109-4.4%
Net Income-$5.01M-159.7%
EBITDA-$4.56M-154.6%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$4.40M-36.2%
Accounts Receivable$1.63M313.4%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$10.72M737.1%
Short Term Debt$0.87M78.9%

Ratios

Q2 2025YOY Change
Return On Assets-68.39%13.0%
Return On Invested Capital-269.51%-157.0%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$4.27M-37.2%
Operating Free Cash Flow-$3.49M-14.6%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book1.402.672.114.22-59.46%
Price to Sales1.181.681.671.99290.31%
Price to Tangible Book Value2.864.613.5415.43-779.28%
Enterprise Value to EBITDA-5.04-7.71-6.30-7.87595.33%
Return on Equity-326.0%-266.3%-450.5%-262.0%-8.06%
Total Debt$1.64M$1.51M$1.40M$11.58M556.52%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.